Literature DB >> 17690571

Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy.

Todd T Brown1, Haitao Chu, Zhaojie Wang, Frank J Palella, Lawrence Kingsley, Mallory D Witt, Adrian S Dobs.   

Abstract

BACKGROUND: The relative contributions of the different classes of antiretroviral therapy (ART), HIV infection per se, and aging to body shape changes in HIV-infected patients have not been clearly defined in longitudinal studies.
METHODS: Since September 1999, men enrolled in the Multicenter AIDS Cohort Study have undergone measurements of body mass index (BMI) and body circumferences at each semi-annual visit. The effect of HIV-serostatus and cumulative exposure to the three major ART classes on changes in anthropomorphic measurements occurring between 1999 and 2004 among HIV-infected and HIV-uninfected men were determined using linear mixed effects regression models.
RESULTS: At baseline, average BMI and circumference measurements were greater in HIV-uninfected men (n = 392) than HIV-infected men (n = 661) (BMI, 27.3 versus 25.3 kg/m; waist, 96.4 versus 90.2 cm; hip 101.3 versus 95 cm, thigh 54.1 versus 50.8 cm; arm 33.3 versus 31.7 cm, P < 0.001 for each comparison). Cumulative nucleoside reverse transcriptase inhibitor (NRTI) exposure, but not protease inhibitor or non-nucleoside reverse transcriptase inhibitor exposure, was associated with statistically significant changes in BMI (-0.11 +/- 0.04 kg/m per year) and in circumferences of waist (-0.27 +/- 0.07 cm/year), hip (-0.24 +/- 0.05 cm/year), and thigh (-0.16 +/- 0.03 cm/year) over the 5 years of follow-up. Independent of ART exposure, HIV-infected men had a more rapid increase in waist circumference over the study interval than did the HIV-uninfected men (difference 0.33 +/- 0.15 cm/year, P = 0.02).
CONCLUSION: Cumulative NRTI therapy was associated with longitudinal decreases in body circumference measurements, whereas HIV-serostatus was associated with increases in waist circumference independent of ART.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690571     DOI: 10.1097/QAD.0b013e328270356a

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  22 in total

1.  HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction.

Authors:  Anne-Lise Paisible; Chung-Chou H Chang; Kaku A So-Armah; Adeel A Butt; David A Leaf; Matthew Budoff; David Rimland; Roger Bedimo; Matthew B Goetz; Maria C Rodriguez-Barradas; Heidi M Crane; Cynthia L Gibert; Sheldon T Brown; Hilary A Tindle; Alberta L Warner; Charles Alcorn; Melissa Skanderson; Amy C Justice; Matthew S Freiberg
Journal:  J Acquir Immune Defic Syndr       Date:  2015-02-01       Impact factor: 3.731

2.  Sexual, behavioral, and quality of life characteristics of healthy weight, overweight, and obese gay and bisexual men: findings from a prospective cohort study.

Authors:  Thomas E Guadamuz; Sin How Lim; Michael P Marshal; Mark S Friedman; Ronald D Stall; Anthony J Silvestre
Journal:  Arch Sex Behav       Date:  2011-10-25

3.  Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa.

Authors:  Alana T Brennan; Kaitlyn M Berry; Sydney Rosen; Andrew Stokes; Nigel J Crowther; Jaya George; Frederick Raal; Naseem Cassim; Ian Sanne; Lawrence Long; Matthew P Fox
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

4.  A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

Authors:  Jordan E Lake; Grace A McComsey; Todd M Hulgan; Christine A Wanke; Alexandra Mangili; Sharon L Walmsley; M Sean Boger; Ralph R Turner; Heather E McCreath; Judith S Currier
Journal:  AIDS Patient Care STDS       Date:  2012-07-23       Impact factor: 5.078

5.  Anthropometry in the prediction of sleep disordered breathing in HIV-positive and HIV-negative men.

Authors:  Todd T Brown; Susheel P Patil; Lisa P Jacobson; Joseph B Margolick; Alison M Laffan; Rebecca J Godfrey; Jacquett R Johnson; Lisette M Johnson-Hill; Sandra M Reynolds; Alan R Schwartz; Philip L Smith
Journal:  Antivir Ther       Date:  2010

Review 6.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

7.  Sex differences in neurocognitive screening among adults living with HIV in China.

Authors:  Xiaotong Qiao; Haijiang Lin; Xiaoxiao Chen; Chenxi Ning; Keran Wang; Weiwei Shen; Xiaohui Xu; Xiaoyi Xu; Xing Liu; Na He; Yingying Ding
Journal:  J Neurovirol       Date:  2019-02-13       Impact factor: 2.643

8.  Longitudinal anthropometric patterns among HIV-infected and HIV-uninfected women.

Authors:  Jessica E Justman; Donald R Hoover; Qiuhu Shi; Tianren Tan; Kathryn Anastos; Phyllis C Tien; Stephen R Cole; Charles Hyman; Roksana Karim; Kathleen Weber; Steven Grinspoon
Journal:  J Acquir Immune Defic Syndr       Date:  2008-03-01       Impact factor: 3.731

9.  Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy.

Authors:  Sher L Hendrickson; Lawrence A Kingsley; Eduardo Ruiz-Pesini; Jason C Poole; Lisa P Jacobson; Frank J Palella; Jay H Bream; Douglas C Wallace; Stephen J O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2009-06-01       Impact factor: 3.731

10.  Fat distribution and longitudinal anthropometric changes in HIV-infected men with and without clinical evidence of lipodystrophy and HIV-uninfected controls: a substudy of the Multicenter AIDS Cohort Study.

Authors:  Todd T Brown; Xiaoqiang Xu; Majnu John; Jaya Singh; Lawrence A Kingsley; Frank J Palella; Mallory D Witt; Joseph B Margolick; Adrian S Dobs
Journal:  AIDS Res Ther       Date:  2009-05-13       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.